The anaplerotic medium-odd-chain triglyceride, triheptanoin, is used in clinical trials for the chronic dietary treatment of patients with long-chain fatty acid oxidation disorders. We previously showed (Kinman et al Am. J. Physiol. 291: E860-E866, 2006), that the intravenous infusion of triheptanoin increases lipolysis traced by the turnover of glycerol. In this study, we tested whether lipolysis induced by triheptanoin infusion is accompanied by the potentially harmful release of long-chain fatty acids. Rats were infused with heptanoate ± glycerol, or triheptanoin. Intravenous infusion of triheptanoin at 40% of caloric requirement markedly increased glycerol Ra but not oleate Ra. Thus, the activation of lipolysis was balanced by fatty acid re-esterification in the same cells. The liver acyl-CoA profile showed the accumulation of intermediates of heptanoate β-oxidation and C5-ketogenesis, a decrease in free CoA, but no evidence of metabolic perturbation of liver metabolism such as propionyl overload. Our data suggest that triheptanoin, administered either intravenously or intraduodenally, could be used for intensive care nutritional support of metabolically decompensated patients including long-chain fatty acid oxidation disorders.
- odd-chain triglycerides
- parenteral nutrition
- fatty acid oxidation disorders
- Copyright © 2009, American Journal of Physiology - Endocrinology and Metabolism